is there a website that will write my essay for me vikings homework help woodlands junior assignment on globalisation thesis helper online help on dissertation global warming graduate school paper writing terminal services default wallpaper petrol station business plan
Skip to main content

D-VLAP

Ref-Nr: TA-5797


Kurzfassung

VEGF-multimer based apheresis to treat preeclampsia


Hintergrund

Preeclampsia is a potentially life-threatening multisystem disease affecting 4% to 8% of pregnant women after the 20th week of gestation (EGA). Around 20% of affected pregnancies have to be terminated before the 34th EGA. An excess of placental expressed anti-angiogenic soluble VEGF-receptor 1 (sFlt-1) scavenges VEGF and PlGF, causing generalized endothelial dysfunction. Interventions to restore the angiogenic balance in preeclamptic pregnancies are intensively studied and improve maternal and neonatal outcomes. Especially extracorporeal strategies to remove sFlt-1 are promising in human pregnancy. However, available apheresis systems adsorb sFlt-1 unspecifically and with low efficiency. Affinity enhanced ligands are needed to improve performance and compatibility of apheresis treatments.


Bilder & Videos


Lösung

Researchers of the University Hospital Cologne have developed VEGF-based sFlt-1 capturing molecules (scVEGF165) characterized by higher affinity for sFlt-1 as compared to competing products and the ability to displace complexed endogenous VEGF and PlGF from its binding to sFlt-1 in patient blood. Thus restoring the angiogenic balance in double action, which will result in shorter treatment duration and more efficient sFlt-1 removal at low sFlt-1 plasma levels. For ex vivo characterization, ligands were immobilized to biocompatible agarose matrix routinely used in medical aphersis systems.


Vorteile

  • Higher affinity for sFlt-1 as compared to competing products
  • Displace complexed endogenous VEGF and PlGF from its binding to sFlt-1
  • Thus restoring the angiogenic balance in double action

Anwendungsbereiche

There is strong interest in novel approaches with regard to extracorporeal therapies for preeclampsia. So far only one company is in the process of developing an antibody-based approach of sFlt-1 apheresis, which is less efficient as compared to this VEGF-based apheresis system. Specifically, the efficient liberation of endogenous VEGF and PlGF is an advantage of this novel approach.


Service

Before rolling out to clinical studies in pregnancies with preeclampsia, toxicity and compatibility, e.g. the safety of endogenous VEGF- and PlGF-release for mother and fetus, has to be tested in vivo. Finally, pivotal clinical trials comparing this novel strategy to the state-of-the-art at this future time point will be needed before approval of this novel medical device.


PROvendis GmbH

Prof. Dr. Frank Entschladen
+49.208 94105-20
fe@provendis.info
www.provendis.info
Adresse
Schloßstr. 11-15
45468 Mülheim an der Ruhr



Entwicklungsstand

Teststadium


Patentsituation

  • EP anhängig

Stichworte

Apheresis, preeclampsia, VEGF, sFlt

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsführerin)

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen